# Calcium and Phosphate Disorders: A Clinical Review

## Clinical Priorities

Interpret calcium and phosphate together with kidney function, magnesium, parathyroid hormone (PTH), vitamin D status, symptoms, and the time course. A concentration outside the reference interval is the beginning of the assessment, not a complete diagnosis. Severe symptomatic abnormalities can be emergencies; chronic treatment depends on the mechanism and can itself injure the kidney if poorly monitored.

## Interpret the Measurement

Serum total calcium includes albumin-bound calcium. A low total value in hypoalbuminemia does not always mean low biologically active ionized calcium. Albumin-correction formulas are imperfect, particularly in critical illness and kidney disease. Measure ionized calcium when the result will guide urgent treatment or when protein binding or pH makes total calcium difficult to interpret. Reference intervals vary by laboratory and age.

For phosphate, consider recent intake, timing, cell shifts, supplements, and sample artifact. Confirm an unexpected isolated abnormality when clinically appropriate. A serum value does not directly quantify whole-body stores. [Moe et al.](https://pubmed.ncbi.nlm.nih.gov/18486714/)

## How Regulation Works

Intestine, bone, and kidney exchange calcium and phosphate. PTH promotes calcium conservation and phosphate excretion by the kidney and stimulates calcitriol production. Calcitriol increases intestinal mineral absorption. FGF23 promotes renal phosphate excretion and suppresses calcitriol synthesis; Klotho participates in its signaling.

### Calcium

The kidney reabsorbs nearly all filtered calcium. Most reabsorption occurs in the proximal tubule and thick ascending limb, with distal transport contributing regulated calcium conservation. Changes in sodium handling, volume, PTH, and medications affect urinary calcium.

### Phosphate

Proximal tubular sodium–phosphate transport is a major determinant of phosphate balance. PTH and FGF23 reduce tubular phosphate reabsorption. In CKD, hormonal adaptation can maintain serum phosphate early, while retention becomes more evident as kidney failure advances. [Blaine et al.](https://pubmed.ncbi.nlm.nih.gov/25287933/)

## Hypocalcemia

Symptoms can include paresthesias, cramps, tetany, seizures, laryngospasm, or arrhythmia. Clinical urgency depends on severity, symptoms, rate of decline, and the ECG rather than one threshold alone.

Evaluate magnesium, phosphate, kidney function, PTH, and vitamin D status. Low or inappropriately normal PTH with hypocalcemia suggests deficient secretion, whereas elevated PTH can accompany vitamin D deficiency, CKD, or hormone resistance. Magnesium deficiency can impair PTH secretion and action. Review neck surgery, malabsorption, antiresorptive treatment, acute pancreatitis, tumor lysis, and other relevant exposures.

Severe acute or symptomatic hypocalcemia may require intravenous calcium with ECG and biochemical monitoring. Use an institutional regimen and reassess frequently. Correct magnesium deficiency. Stable chronic disease is often managed with oral calcium and appropriate vitamin D therapy; hypoparathyroidism may require active vitamin D and specialist consideration of hormone replacement. Avoid overcorrection, hypercalciuria, nephrolithiasis, and nephrocalcinosis. [Pepe et al.](https://pubmed.ncbi.nlm.nih.gov/32367335/)

## Hypercalcemia

Possible manifestations include polyuria, dehydration, constipation, weakness, cognitive change, AKI, and cardiac electrical abnormalities. Measure PTH early after confirming the abnormality. An elevated or inappropriately nonsuppressed PTH points toward PTH-dependent disease; suppressed PTH prompts evaluation for malignancy, vitamin D-related mechanisms, medications, and other causes.

Review calcium and vitamin D products, thiazides, lithium, and relevant cancer or granulomatous-disease history. Urinary calcium can help assess familial hypocalciuric hypercalcemia, but low intake, CKD, thiazides, and other factors complicate interpretation. Parathyroid imaging is used for operative planning after biochemical diagnosis; a negative scan does not exclude primary hyperparathyroidism. [Wilhelm et al.](https://pubmed.ncbi.nlm.nih.gov/27532368/)

For severe or symptomatic hypercalcemia, restore volume when depleted, with careful reassessment in heart failure or kidney disease. Loop diuretics are reserved for management of fluid overload when needed, not routine calcium lowering. The need for kidney replacement therapy depends on severity, treatment response, and the ability to manage fluids and electrolytes. [Walsh et al.](https://pubmed.ncbi.nlm.nih.gov/27935816/)

For hypercalcemia of malignancy, the Endocrine Society recommends an intravenous bisphosphonate or denosumab and conditionally favors denosumab over an IV bisphosphonate on low-certainty evidence. Severe presentations may also receive calcitonin initially; its effect is limited by tachyphylaxis. Choice of therapy must account for kidney function and hypocalcemia risk. Treat the malignancy to reduce recurrence. Calcitriol-mediated hypercalcemia and primary hyperparathyroidism require different cause-directed strategies. [El-Hajj et al.](https://pubmed.ncbi.nlm.nih.gov/36545746/)

## Hyperphosphatemia

Reduced renal excretion is common in advanced CKD. Other causes include a large phosphate load, cell breakdown, and hormonal abnormalities. Review phosphate-containing preparations, tumor lysis, rhabdomyolysis, kidney function, calcium, and PTH. Severe acute phosphate release can lower calcium and requires urgent assessment of the underlying process.

In CKD, interpret serial calcium, phosphate, and PTH together. Base phosphate-lowering treatment on persistent or progressive elevation rather than one isolated value. Dietary advice should consider phosphate additives, bioavailability, adequate protein, and nutritional status. Binders are taken with meals when indicated; select them according to calcium balance, other adverse effects, pill burden, access, and the overall CKD-MBD pattern. Restrict excessive calcium-based binder exposure and avoid aluminum toxicity.

Dialysis prescription, dietary measures, and medications may all contribute. Lowering a laboratory value is not automatically proof of improved survival. CKD-MBD also encompasses bone turnover, mineralization, and vascular calcification, so treatment should be individualized rather than driven by a fixed calcium–phosphate product. [Ketteler et al.](https://pubmed.ncbi.nlm.nih.gov/29459980/); [Ketteler et al.](https://pubmed.ncbi.nlm.nih.gov/39864017/)

## Hypophosphatemia

Three broad mechanisms are decreased absorption, increased urinary loss, and movement into cells. Refeeding, insulin treatment, respiratory alkalosis, malnutrition, alcohol-related illness, phosphate-binding drugs, proximal tubular dysfunction, and inherited or acquired FGF23 disorders can contribute.

Assess symptoms and the clinical setting. Severe depletion can impair respiratory muscle and cardiac function and accompany rhabdomyolysis or hemolysis; chronic phosphate wasting may cause bone pain, fractures, rickets, or osteomalacia. When the cause remains uncertain, assess renal phosphate handling using appropriately timed blood and urine measurements. Interpret urinary excretion in relation to the low serum phosphate and recent supplementation. [Imel et al.](https://pubmed.ncbi.nlm.nih.gov/22392950/)

Stable mild or moderate deficiency often permits oral treatment and correction of the cause. Severe symptomatic deficiency, inability to absorb oral therapy, or selected critical illness may require IV phosphate. Dose and rate depend on severity, kidney function, body size, potassium, calcium, and ongoing shifts. Use a monitored local protocol rather than a universal weight-based ceiling. IV replacement can cause hypocalcemia, arrhythmia, potassium disturbance, and tissue calcium-phosphate deposition; kidney impairment increases risk.

Chronic renal phosphate wasting needs a specific diagnosis. Conventional phosphate and active-vitamin-D treatment or targeted treatment may be appropriate for selected disorders under specialist care. Avoid applying a regimen for inherited phosphate wasting to transient redistribution during acute illness. [Felsenfeld et al.](https://pubmed.ncbi.nlm.nih.gov/22863286/)

## Monitoring and Special Situations

Check what has already been administered before repeating replacement. Coordinate calcium, magnesium, potassium, and phosphate orders because correcting one abnormality can change another. Review drug interactions, absorption, and dialysis losses. During refeeding or treatment of severe acute disturbances, monitoring is more frequent than during stable chronic management.

In CKD, avoid assuming that a low total calcium always requires immediate calcium loading. Balance symptoms and ionized calcium against phosphate burden and calcification risk. Children, pregnancy, inherited disorders, and patients receiving antiresorptive drugs may need a specialist plan. Specify the repeat-laboratory schedule and escalation criteria at discharge.

## Takeaways

Confirm the relevant measurement, identify the dominant mechanism, and treat urgent symptoms promptly. Use PTH, magnesium, vitamin D, and kidney function to narrow the diagnosis. Replace minerals cautiously with planned reassessment, and distinguish acute rescue therapy from long-term treatment.

## References

1.  Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. *Clin J Am Soc Nephrol* 2015. [PubMed 25287933](https://pubmed.ncbi.nlm.nih.gov/25287933/).
2.  Moe SM. Disorders involving calcium, phosphorus, and magnesium. *Prim Care* 2008. [PubMed 18486714](https://pubmed.ncbi.nlm.nih.gov/18486714/).
3.  Pepe J, Colangelo L, Biamonte F, et al. Diagnosis and management of hypocalcemia. *Endocrine* 2020. [PubMed 32367335](https://pubmed.ncbi.nlm.nih.gov/32367335/).
4.  El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2023. [PubMed 36545746](https://pubmed.ncbi.nlm.nih.gov/36545746/).
5.  Walsh J, Gittoes N, Selby P, et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute hypercalcaemia in adult patients. *Endocr Connect* 2016. [PubMed 27935816](https://pubmed.ncbi.nlm.nih.gov/27935816/).
6.  Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. *JAMA Surg* 2016. [PubMed 27532368](https://pubmed.ncbi.nlm.nih.gov/27532368/).
7.  Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. *Ann Intern Med* 2018. [PubMed 29459980](https://pubmed.ncbi.nlm.nih.gov/29459980/).
8.  Ketteler M, Evenepoel P, Holden RM, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2025. [PubMed 39864017](https://pubmed.ncbi.nlm.nih.gov/39864017/).
9.  Imel EA, Econs MJ. Approach to the hypophosphatemic patient. *J Clin Endocrinol Metab* 2012. [PubMed 22392950](https://pubmed.ncbi.nlm.nih.gov/22392950/).
10. Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. *Am J Kidney Dis* 2012. [PubMed 22863286](https://pubmed.ncbi.nlm.nih.gov/22863286/).


---

[Website version](https://urinenephrology.org/mastery/electrolytes-advanced/calcium-phosphate-review.html) · Markdown synchronized October 3, 2026.